2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

J. Herrstedt, R. Clark-Snow, C. H. Ruhlmann, A. Molassiotis, I. Olver, B. L. Rapoport, M. Aapro, K. Dennis, P. J. Hesketh, R. M. Navari, L. Schwartzberg, M. L. Affronti, M. A. Garcia-Del-Barrio, A. Chan, L. Celio, R. Chow, M. Fleury, R. J. Gralla, R. Giusti, F. JahnH. Iihara, E. Maranzano, V. Radhakrishnan, M. Saito, P. Sayegh, S. Bosnjak, L. Zhang, J. Lee, V. Ostwal, T. Smit, A. Zilic, K. Jordan, F. Scotté*, participants of the MASCC/ESMO Consensus Conference 2022

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

49 Downloads (Pure)

Abstract

• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade). • All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.

Original languageEnglish
Article number102195
JournalESMO Open
Volume9
Issue number2
Number of pages18
ISSN2059-7029
DOIs
Publication statusPublished - Feb 2024

Keywords

  • chemotherapy
  • MASCC–ESMO Clinical Practice Guideline
  • nausea and vomiting
  • prevention
  • radiotherapy
  • Humans
  • Nausea/prevention & control
  • Radiation Oncology
  • Vomiting/prevention & control

Fingerprint

Dive into the research topics of '2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting'. Together they form a unique fingerprint.

Cite this